Floatz logo

ltt462

Other Solid Tumors

Novartis PharmaceuticalsPhase 1Dormant
D
27/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
12/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Other Solid Tumors cohort.

Asset / SponsorPhaseRating
Epirubicin
Karyopharm Therapeutics Inc
Phase 1/2B
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
Memorial Sloan Kettering Cancer Center
Phase 2B
Cyclophosphamide
National University Hospital, Singapore
Phase 1/2B
Pembrolizumab
Evopoint Biosciences Inc.
Phase 1/2B
Fludarabine
National University Hospital, Singapore
Phase 1/2CCC

View all 46 →

Same molecule, other indications

ltt462 is also rated in:

melanomaDormant
C
Indicative ·
37 / 100
View asset →
ovarian neoplasmDormant
D
Indicative ·
27 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
27 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →